Clinical Trial

A Study of Simmitinib Plus SG001 in Advanced Solid Tumors

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is an open-label Phase I/II trial of simmitinib plus SG001 in patients with advanced solid tumors. Phase I will determine and confirm the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) for simmitinib in combination with SG001 in patients with advanced solid tumors. Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 3 cohorts at the RP2D from Phase I.
Trial Details
NCT Number NCT06132217
Lead Sponsor Shanghai Runshi Pharmaceutical Technology Co., Ltd
Conditions Advanced Solid Tumor
Enrollment 168 participants
Start Date 2024-01-30
Primary Completion 2027-01-30 (estimated)
Study Completion 2027-01-30 (estimated)
Updated on ClinicalTrials.gov 2023-11-15